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Abstract 
Introduction: The prognosis of advanced gastric cancer patients, especially those with 
poor performance status (PS), is generally dismally poor. Patients with PS 3–4 are usually 
ineligible for participation in clinical studies and are managed with only best supportive 
care.  
Case Report: A 63-year-old male with advanced gastric cancer was admitted to our 
hospital. His PS was markedly impaired (Eastern Cooperative Oncology Group PS 4), with 
dyspnea secondary to lymphangitis, pleuritis and pericarditis). He also had bilateral leg 
paralysis due to multiple bone metastases. He was treated with chemotherapy using 5-
fluorouracil and leucovorin for 14 days with pericardial drainage followed by 
intrapericardial infusion of cisplatin. He was also treated with radiotherapy for bone 
metastasis. The patient required 5 l/min oxygen therapy at the start of chemotherapy, 
but his dyspnea was improved by day 14 and he no longer required supplemental 
oxygen therapy. His leg paralysis also improved with the radiation therapy. His PS was 
significantly improved with this multimodal treatment modality, and he was ultimately 
discharged with chemotherapy with oral fluoropyrimidine.  
Conclusion: This case suggests that multimodal therapy including chemotherapy may be 
beneficial in advanced gastric cancer patients even in the setting of poor PS. Further 
study might be required to confirm the benefit of chemotherapy in this patient 
population. 
Introduction 
Performance status (PS) is a strong independent prognostic factor for survival in 
patients with advanced gastric cancer [1, 2]. In general, patients selected for participation 
in clinical trials are required to have an Eastern Cooperative Oncology Group (ECOG) PS  
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≤2. In fact, the majority of patients in cancer clinical trials have an ECOG PS 0–1, with 
less than 10% having a PS 2. Few clinical trials targeting ECOG PS 3 or 4 gastrointestinal 
cancer patients have been reported [3, 4]; thus, such patients are not generally considered 
to be candidates for chemotherapy. According to the US National Comprehensive Cancer 
Network (NCCN) clinical practice guidelines for gastric cancer [5], patients with an 
ECOG PS 3–4 should only be offered best supportive care. Despite these 
recommendations, some gastric cancer patients in clinical practice with a deteriorated PS 
wish to receive chemotherapy. Here we report a case of an advanced gastric cancer patient 
with poor PS (ECOG PS 4) whose PS improved with chemotherapy and radiotherapy. 
Case Presentation 
A 63-year-old Japanese male was admitted to our hospital with worsening dyspnea, cough and 
anorexia for 1 month. He also had noticed bilateral leg paralysis for 2 weeks. One year before admission, 
he was diagnosed as having gastric cancer with pathological evidence of a poorly-differentiated 
adenocarcinoma for which he refused to undergo any surgical or medical treatment. On admission, his 
physical examination was notable for decreased respiratory sounds in bilateral lower lungs. His oxygen 
saturation was 86% on room air and 96% with 2 l/min oxygen administration. He also demonstrated 
bilateral leg weakness. Chest X-ray on admission showed an enlarged cardiac silhouette, with a 
cardiothoracic ratio of 60%. His laboratory results were notable for increased serum liver enzymes 
(aspartate transaminase 1,149 IU/l, alanine transaminase 965 IU/l, lactate dehydrogenase 1,580 IU/l). 
Echocardiography showed pericardial effusions with triphasic flow with increased retrograde amplitude 
in the inferior vena cava on duplex Doppler sonogram, which was suspected to be caused by increased 
right heart pressure during the cardiac cycle. Therefore, emergent pericardiocentesis was performed, 
and the drainage tube was left in the pericardial space. The total volume of effusions was approximately 
500 ml at day 1, 300 ml at day 2 and 200 ml at day 3. Malignant adenocarcinoma cells were detected in 
cytologic analysis of the effusion. Although his liver dysfunction was improved by pericardial drainage, 
his dyspnea worsened, which required increment of O2 administration (5 l). A computed tomography 
(CT) scan showed extensive infiltration of the lung and bilateral pleural effusions, compatible with 
lymphangitic carcinomatosis (fig. 1a, b). Abdominal CT scan showed para-aortic lymph node 
metastasis and ascites (fig. 2a, b). Bone scan revealed multiple bone metastases at cervical and thoracic 
vertebrae (C7 to Th7). Although he had PS 4 with dyspnea requiring oxygen administration, he strongly 
wished to receive chemotherapy. Therefore, combination therapy consisting of 5-fluorouracil (5-FU) 
and leucovorin (LV) was initiated. The dose and administration schedule were planned as follows: 
infusional 5-FU (250 mg/m
2) in 24 h and LV (25 mg/m
2) in 1 h, on days 1–14 every 21 days. Although 
his respiratory status was transiently worsened and oxygen administration was increased to 7 l on day 3 
(fig. 3a), it improved thereafter, and oxygen administration was discontinued at day 14. Because his leg 
weakness worsened soon after the initiation of chemotherapy, radiotherapy for bone metastasis (total 30 
Gy) was also performed. The amount of pericardial effusions from the drainage tube decreased to 100 
ml/day at the end of 5-FU plus LV treatment, and the catheter was removed after intracavitary 
treatment with a 30 mg bolus of cisplatin. His course was complicated by grade 2 stomatitis secondary 
to the chemotherapy; this improved within 1 week. His oral intake improved concurrent with the 
improvement of PS, and chemotherapy using oral fluoropyrimidine of S-1 was initiated after 
completion of infusional chemotherapy, approximately 2 months after his initial presentation. Chest X-
ray and CT scan prior to S-1 chemotherapy showed improved extensive lung infiltration and ascites (fig. 
1c, d, 2c, d, 3b). His PS was well maintained (PS 1) with chemotherapy administered on an outpatient 
basis. However, his tumor returned after 5 months of oral chemotherapy. Although he was treated with 
second-line chemotherapy using paclitaxel, he passed away 2 months later, approximately 9 months 
after his initial admission. 
Discussion 
As a result of disease progression, patients with gastric cancer experience several 
complications, including anorexia, fatigue, abdominal distension and dyspnea, which can 
lead to deterioration of general patient status. The prognosis of advanced gastric cancer 
patients, particularly those with an ECOG PS 3–4, is dismally poor. Usually, best  
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supportive care without chemotherapy is offered to these patients [5]. However, 
according to our previous report [6] which evaluated 116 gastrointestinal cancer patients 
with PS 3–4 who received chemotherapy (including 37 gastric cancer patients), 32.7% 
achieved a tumor response, or a decrease in accumulated fluid, or a decline in tumor 
markers, resulting in a survival benefit compared to the other patients without any effect 
(6.9 months vs. 2.2 months, p < 0.001). Also, improvement in the PS for a duration of 
more than 4 weeks was seen in 13.8% of the patients with a low incidence of toxicity-
related death (0.8%). These results and this case report suggest that chemotherapy might 
be beneficial in some gastric cancer patients, even those with a poor PS. However, the 
effect of chemotherapy may not be sufficient to achieve an improvement in PS, as 
evidenced by our use of multimodal therapy in this patient. Therefore, further study 
might be required to investigate which patients might gain benefit from chemotherapy. 
For example, gefitinib for patients with lung adenocarcinoma harboring mutation in 
epidermal growth factor receptor results in PS improvement of 79% and median survival 
time of 17.8 months even in patients with poor PS [7]. The development of targeted 
therapies for gastric cancer should also allow the delivery of tailored treatment more 
adequate for individual patients through molecular profiling of their tumors. Finally, it is 
important to consider the patient’s opinion due to the lack of sufficient evidence and the 
modest improvement in survival obtained with chemotherapy in advanced gastric cancer. 
Conclusion 
Our case suggests that multimodal therapy including chemotherapy may be beneficial 
in advanced gastric cancer patients even in the setting of poor PS. 
Consent 
Written informed consent was obtained from the patient’s wife for publication of this case report 
and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief 
of this journal. 
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Fig. 1. a, b CT scan prior to chemotherapy with 5-FU plus leucovorin. Extensive infiltration of the lung 
and bilateral pleural effusions are shown, compatible with lymphangitis carcinomatosis. c, d CT scan 
prior to chemotherapy with S-1. Lung infiltration and bilateral pleural effusions had nearly disappeared. 
 
 
 
Fig. 2. a, b CT scan prior to chemotherapy with 5-FU plus leucovorin. Bilateral pleural effusions, 
ascites and para-aortic lymph node metastases were seen. Pericardial tube was inserted at apex (white 
arrowhead). c, d CT scan prior to chemotherapy with S-1. Bilateral pleural effusions and ascites had 
nearly disappeared. Para-aortic lymph node metastases were reduced in size. 
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Fig. 3. a Chest X-ray at day 3 of chemotherapy with 5-fluorouracil and leucovorin, demonstrating 
extensive infiltration of the lung. b Chest X-ray prior to chemotherapy with S-1. Extensive lung 
infiltration has disappeared. 
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